AGLE Aeglea BioTherapeutics, Inc. Stock Quote

publish chart | save to portfolio | create alert

AGLE [NASD]

Aeglea BioTherapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.91	Insider Own	2.53%	Shs Outstand	62.24M	Perf Week	-4.76%
Market Cap	396.80M	Forward P/E	-	EPS next Y	-1.32	Insider Trans	0.00%	Shs Float	46.72M	Perf Month	3.54%
Income	-79.70M	PEG	-	EPS next Q	-0.31	Inst Own	88.00%	Short Float	5.96%	Perf Quarter	12.33%
Sales	-	P/S	-	EPS this Y	-15.00%	Inst Trans	2.07%	Short Ratio	9.97	Perf Half Y	-7.76%
Book/sh	2.19	P/B	3.74	EPS next Y	12.00%	ROA	-66.90%	Target Price	-	Perf Year	5.94%
Cash/sh	2.89	P/C	2.83	EPS next 5Y	-	ROE	-81.40%	52W Range	3.50 - 11.38	Perf YTD	7.33%
Dividend	-	P/FCF	-	EPS past 5Y	-22.00%	ROI	-	52W High	-27.94%	Beta	1.70
Dividend %	-	Quick Ratio	10.10	Sales past 5Y	-	Gross Margin	-	52W Low	134.29%	ATR	0.46
Employees	87	Current Ratio	10.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	43.68	Volatility	4.49% 5.75%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	55.80%	Profit Margin	-	Rel Volume	1.38	Prev Close	8.23
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 05 BMO	Payout	-	Avg Volume	279.40K	Price	8.20
Recom	2.10	SMA20	-7.58%	SMA50	0.66%	SMA200	10.68%	Volume	386,555	Change	-0.36%

May-04-20

Initiated

Piper Sandler

Overweight

$12

Mar-21-19

Initiated

JP Morgan

Overweight

$14

Sep-04-18

Downgrade

Wells Fargo

Outperform → Market Perform

Apr-24-18

Initiated

Evercore ISI

Outperform

$37

Mar-14-18

Reiterated

Needham

Buy

$8 → $12

Dec-01-20 07:30AM	Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria PR Newswire
Nov-24-20 04:40PM	Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference PR Newswire
Nov-17-20 04:30PM	Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences PR Newswire
Nov-10-20 05:40AM	How Much Are Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Insiders Spending On Buying Shares? Simply Wall St. +13.10%
Nov-05-20 08:30AM	Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights PR Newswire +8.08%
Nov-03-20 08:44AM	Is a Surprise Coming for Aeglea (AGLE) This Earnings Season? Zacks +5.68%
Oct-26-20 08:30AM	Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria PR Newswire -5.60%
Oct-13-20 12:35PM	Hedge Funds Are Crazy About Aeglea BioTherapeutics, Inc. (AGLE) Insider Monkey
Oct-05-20 04:30PM	Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings PR Newswire
Sep-11-20 06:39AM	Is Aeglea BioTherapeutics (NASDAQ:AGLE) In A Good Position To Invest In Growth? Simply Wall St.
Sep-02-20 04:05PM	Aeglea BioTherapeutics to Participate in September Investment Conferences GlobeNewswire
Aug-25-20 08:40AM	Aeglea (AGLE) Looks Good: Stock Adds 5.8% in Session Zacks
Aug-18-20 04:05PM	Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020 GlobeNewswire
Aug-10-20 08:30AM	Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights GlobeNewswire
Jul-13-20 09:28AM	How Should Investors React To Aeglea BioTherapeutics' (NASDAQ:AGLE) CEO Pay? Simply Wall St. -5.31%
Jun-30-20 11:25PM	Were Hedge Funds Right About Buying Aeglea BioTherapeutics, Inc. (AGLE)? Insider Monkey
Jun-29-20 12:00PM	Here's Why Momentum Investors Will Love Aeglea Biotherapeutics (AGLE) Zacks
Jun-26-20 11:30AM	Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year? Zacks -6.40%
Jun-23-20 08:47AM	Aeglea BioTherapeutics (AGLE) Catches Eye: Stock Jumps 5.1% Zacks -11.37%
Jun-10-20 11:30AM	Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year? Zacks
Jun-08-20 09:03AM	Why Aeglea BioTherapeutics (AGLE) Stock Might be a Great Pick Zacks
Jun-04-20 11:17AM	Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio Zacks
Jun-01-20 04:05PM	Aeglea BioTherapeutics to Present at BIO Digital 2020 GlobeNewswire
May-29-20 11:49AM	Aeglea BioTherapeutics' Shares March Higher, Can It Continue? Zacks
May-28-20 04:10PM	Aeglea BioTherapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held June 8, 2020 GlobeNewswire
May-27-20 08:43AM	Menlo Therapeutics (MNLO) Catches Eye: Stock Jumps 7.1% Zacks
May-26-20 08:30AM	Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology GlobeNewswire
May-21-20 11:30AM	Is Aeglea BioTherapeutics (AGLE) Outperforming Other Medical Stocks This Year? Zacks
May-20-20 08:56AM	Zacks.com featured highlights include: Aeglea BioTherapeutics, VeriSign, Sequans Communications and New Jersey Resources Zacks
May-19-20 07:26PM	Find Strong Stocks During the Coronavirus with New Analyst Coverage Zacks +7.82%
10:10AM	4 Stocks in the Limelight on New Analyst Coverage Zacks
08:30AM	Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology GlobeNewswire
May-07-20 08:41AM	Is Aeglea BioTherapeutics (AGLE) Stock a Solid Choice Right Now? Zacks +5.50%
08:30AM	Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights GlobeNewswire
May-06-20 09:31AM	Aeglea BioTherapeutics, Inc. (AGLE) Shares March Higher, Can It Continue? Zacks -7.90%
06:19AM	Anthony Quinn Is The President of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) And They Just Picked Up 44% More Shares Simply Wall St.
May-05-20 12:00PM	Aeglea (AGLE) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
Apr-30-20 04:05PM	Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Apr-28-20 09:07AM	Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering GlobeNewswire +28.02%
Apr-27-20 04:01PM	Aeglea BioTherapeutics Announces Proposed Public Offering GlobeNewswire
Apr-08-20 07:30AM	Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177) GlobeNewswire +7.42%
Mar-29-20 08:31AM	Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Particularly Volatile Share Price? Simply Wall St.
Feb-24-20 07:30AM	Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones GlobeNewswire -5.72%
Feb-13-20 05:37AM	Should Aeglea BioTherapeutics (NASDAQ:AGLE) Be Disappointed With Their 66% Profit? Simply Wall St.
Jan-13-20 07:00AM	Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177) GlobeNewswire
Jan-08-20 05:11AM	Is Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) CEO Salary Justified? Simply Wall St.
Jan-06-20 04:05PM	Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-12-19 07:08PM	Hedge Funds Are Dumping Aeglea BioTherapeutics, Inc. (AGLE) Insider Monkey
Dec-03-19 05:22AM	Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Insiders Increased Their Holdings Simply Wall St.
Nov-26-19 08:30AM	Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-06-19 08:30AM	Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights GlobeNewswire
Nov-04-19 08:30AM	Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer GlobeNewswire
Oct-10-19 08:54AM	Will Aeglea BioTherapeutics (NASDAQ:AGLE) Spend Its Cash Wisely? Simply Wall St.
Sep-04-19 11:22AM	Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Volatile Share Price? Simply Wall St.
Sep-03-19 06:00AM	Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium GlobeNewswire
Aug-29-19 08:30AM	Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium GlobeNewswire
Aug-06-19 08:00AM	Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights GlobeNewswire
Jul-25-19 07:21AM	The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug Benzinga +19.58%
Jul-24-19 04:05PM	Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency GlobeNewswire
Jul-17-19 03:47PM	Can We See Significant Institutional Ownership On The Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Share Register? Simply Wall St.
Jun-14-19 08:15PM	Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $196,535 of Shares GuruFocus.com
Jun-11-19 07:37PM	Hedge Funds Have Never Been This Bullish On Aeglea BioTherapeutics, Inc. (AGLE) Insider Monkey
Jun-03-19 08:30AM	Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency GlobeNewswire
May-30-19 08:30AM	Aeglea BioTherapeutics to Participate in Upcoming Investor and Industry Conferences GlobeNewswire
May-24-19 10:30AM	These 3 Biotech Stocks Are Attracting Insider Buying TheStreet.com
May-22-19 07:15PM	Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $180,028 of Shares GuruFocus.com
May-07-19 07:51AM	Aeglea: 1Q Earnings Snapshot Associated Press
07:45AM	Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights GlobeNewswire
Apr-27-19 09:11AM	Have Insiders Been Selling Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Shares? Simply Wall St.
Apr-08-19 10:30AM	Aeglea (AGLE) Reports New Positive Data for Pegzilarginase Zacks -7.75%
Apr-07-19 07:15PM	Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders GlobeNewswire
Apr-01-19 08:00AM	Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders GlobeNewswire
Mar-28-19 08:30AM	Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Mar-12-19 05:41PM	Edited Transcript of AGLE earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-08-19 12:44AM	Aeglea BioTherapeutics (AGLE) Q4 2018 Earnings Conference Call Transcript Motley Fool
Mar-07-19 04:05PM	Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights GlobeNewswire
Mar-06-19 01:41PM	The Aeglea BioTherapeutics Share Price Is Up 11% And Shareholders Are Holding On Simply Wall St.
Feb-28-19 08:00AM	Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call GlobeNewswire
Feb-07-19 09:12AM	Aeglea aims to raise $60M for treating rare diseases American City Business Journals
Feb-06-19 12:15AM	Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering GlobeNewswire -19.15%
Feb-05-19 05:15PM	Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-29-19 09:57AM	How Much Of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Do Institutions Own? Simply Wall St.
Jan-02-19 09:09AM	Austin's top-performing stocks of 2018 American City Business Journals +7.34%
Dec-23-18 07:52AM	Is Aeglea BioTherapeutics, Inc. (AGLE) A Good Stock To Buy? Insider Monkey
Dec-14-18 12:59PM	What Investors Should Know About Aeglea BioTherapeutics, Inc.s (NASDAQ:AGLE) Financial Strength Simply Wall St.
Dec-11-18 04:05PM	Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency GlobeNewswire
Dec-06-18 04:05PM	Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference GlobeNewswire -5.30%
Nov-20-18 08:00AM	Aeglea BioTherapeutics to Present at Evercore ISI HealthconX Conference GlobeNewswire
Nov-14-18 07:45AM	Report: Exploring Fundamental Drivers Behind Aeglea BioTherapeutics, Barnes & Noble Education, GSI Technology, Morgan Stanley, FTS International, and Crown Crafts New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-08-18 09:12AM	Aeglea: 3Q Earnings Snapshot Associated Press
08:00AM	Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
Oct-26-18 08:00AM	Aeglea BioTherapeutics to Present Preclinical Data on a New Pipeline Therapeutic for Cystinuria in an Oral Presentation at the 2018 American Society of Nephrology (ASN) Annual Meeting GlobeNewswire
Oct-22-18 08:00AM	Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress GlobeNewswire
Oct-19-18 08:00AM	Aeglea BioTherapeutics to Present Preclinical Data on New Pipeline Therapeutic for Homocystinuria at 2018 American Society of Human Genetics (ASHG) Conference GlobeNewswire -6.06%
Oct-17-18 07:00AM	Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency GlobeNewswire
Oct-10-18 08:00AM	Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting GlobeNewswire -7.05%
Oct-01-18 08:00AM	FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency GlobeNewswire
Sep-28-18 02:14PM	Is Now The Right Time To Invest In Healthcare And Aeglea BioTherapeutics Inc (NASDAQ:AGLE)? Simply Wall St.
Sep-17-18 08:00AM	Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology GlobeNewswire
Sep-04-18 03:03PM	Aeglea Plunges On Updated Data For Arginase 1 Deficiency Candidate, Wells Fargo Downgrade Benzinga -15.46%

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Quinn Anthony G.	President & CEO	Apr 30	Buy	4.75	165,000	783,750	538,469	May 04 07:30 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience